The survival and prognostic factors of primary testicular lymphoma- two-decade single-center experience
The survival and prognostic factors of primary testicular lymphoma- two-decade single-center experience作者机构：Department of Urology Peking University Third Hospital Beijing 100191 China Department of Hematology Peking University Third Hospital Beijing 100191 China Department of Biostatistics Peking University Third Hospital Beijing 100191 China Department of Pathology Peking University Third Hospital Beijing 100191 China
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2018年第20卷第6期
页 面：615-620页
核心收录：
学科分类：090603[农学-临床兽医学] 081702[工学-化学工艺] 08[工学] 0817[工学-化学工程与技术] 09[农学] 0906[农学-兽医学]
基 金：supported by the Fund for Fostering Young Scholars of Peking University Health Science Center
主 题：local treatment modalities prognostic factors prophylaxis contralateral orchiectomy prophylaxis contralateral radiotherapy testicular lymphoma
摘 要：This study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma （PTL） patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for analysis. The Kaplan-Meier method, Log-rank test, and multivariate Cox proportional hazard regression analysis were applied to evaluate progression-free survival （PFS）, overall survival （OS）, and determine prognosis predictors. The median follow-up time was 30 months. Median OS and PFS were 96 months and 49 months, respectively. In univariate analysis, advanced Ann Arbor stage （Ill/IV） （P 〈 0.001）, B symptoms （P 〈 0.001）, and extranodal involvement other than testis （P = 0.001） were significantly associated with shorter OS and PFS. In multivariate analysis, Ann Arbor stage was significantly associated with OS （OR = 11.58, P = 0.049）, whereas B symptom was significantly associated with PFS （OR = 11.79, P = 0.049）. In the 10 patients with the systemic usage of rituximab, bilateral intervention could improve median OS from 16 to 96 months （P = 0.032）. The study provides preliminary evidence on bilateral intervention in testes in the rituximab era and validates common prognostic factors for Chinese PTL patients.
维普期刊数据库
